European procurement teams evaluating Indian CDMOs converge on a surprisingly narrow set of questions during due diligence. Most of them are not about chemistry. They are about whether the paperwork behind the chemistry will survive an MHRA or EMA inspection — because a failed inspection isn't a technical problem for the buyer, it's a supply-chain problem.
This is a field guide to the questions we hear most often when a European buyer walks our facility for the first time, and how we recommend Indian CDMOs answer them. If you're evaluating a supplier and don't know what to look for, use this as a checklist.
Why inspection outcomes have become a currency
Ten years ago, European procurement decisions rested largely on cost, lead time, and existing relationships. Today those factors still matter, but they sit on top of a regulatory floor: if you can't demonstrate a clean inspection history and a functioning quality system, you don't clear the initial screen.
The shift has two drivers. First, medicine shortages caused by supplier-side compliance failures have become a policy issue. Second, EU sponsors are increasingly held responsible for supplier quality — not just their own — under the QP responsibility framework.
The questions MHRA inspectors actually ask
There is no single MHRA inspection script — inspectors focus differently on active pharmaceutical ingredient (API) sites, finished-dosage sites, and biologicals. But across our engagements with European buyers, the same six focus areas come up repeatedly.
- Batch record integrity
- Are records signed at each step by the operator and reviewed by a named QA person? No 'signed after the fact' patterns; no missing entries; no rework of raw data.
- Deviation and CAPA closure
- Is every deviation investigated with a formal root-cause analysis? Is CAPA effectiveness verified at a defined interval, not just closed on paper?
- Change control
- Are all changes — process, equipment, supplier, method — driven through change control before implementation? Retrospective approvals are a red flag.
- Data integrity (ALCOA+)
- Are QC data audit trails enabled and reviewed? Do analysts have distinct logins? Are computerised systems validated with periodic re-review?
- Cleaning validation
- Is the cleaning validation programme lifecycle-managed with periodic revalidation, or a one-time exercise from 2018 that no one has looked at since?
- Supplier oversight
- For starting materials and key intermediates: is there a documented supplier qualification programme, with recent on-site audits and current CoAs on file?
Batch record integrity — what to look for
Ask to see a batch record for a molecule in current commercial supply, not a sanitized specimen. Look at the operator signatures — the same handwriting on multiple critical steps within minutes suggests the operator was not physically at each unit operation. Look at the QA review section — a QA signature 30 seconds after the operator signature suggests rubber-stamping.
Deviation logs — the honesty test
A CDMO with zero deviations in the last twelve months is not a well-run site. It is a site where deviations aren't being captured. Ask for the deviation log by month; a healthy site has 5-15 minor deviations per month with fast closure and a small tail of majors under investigation.
What 'inspection ready' actually means
The phrase 'inspection ready' is often used as a marketing claim. Operationally it means a very specific thing: the site could welcome an inspector at any moment without a pre-inspection sprint.
- Batch records are complete within one shift of the batch closing, not a week later.
- Deviation investigations kick off within 24 hours, with a target closure inside the SOP-defined interval.
- The QA head can produce the last twelve months of deviations, CAPAs, and OOS investigations from memory or a single query.
- Every SOP is version-controlled with an effective date and a scheduled review date that isn't overdue.
- The computerised-system validation package for QC instruments is current and reviewed at least annually.
None of the above is exotic. All of it costs money to maintain. The difference between a regulatory-first CDMO and a cost-first one is largely a difference in what falls off when the schedule gets tight.
A short checklist for Indian CDMO due diligence
- Ask for the full text of the last three regulatory inspection reports, including majors and minors — not just a summary.
- Ask to see a batch record for a molecule in current commercial supply, and read it end-to-end.
- Ask for the deviation log for the last twelve months and note the ratio of minors to majors.
- Ask who signs the batch records — the name of the person, not just 'QA'.
- Ask when the last cleaning validation revalidation was done, and what triggered it.
- Ask which auditor bodies have been on-site in the last 24 months (client audits, third-party, regulatory).
- Ask about their approach to nitrosamines — a site with no nitrosamine risk assessment on any molecule is not modern.
- Ask to speak with the QA head directly. Ten minutes with them tells you more than a two-hour marketing session.
The shift toward regulatory-first CDMO selection
Cost-driven CDMO selection remains common, but the buyers who are winning long-term supply contracts today lead with regulatory posture and treat cost as a downstream variable. It is not that they are willing to pay a premium indefinitely; it is that they've been burned by cheap suppliers who couldn't clear the second inspection.
For Indian CDMOs, the strategic implication is clear: invest in the quality system and let the chemistry follow. It's harder to fake a QA framework than to fake a slick facility tour.
“We stopped screening for the cheapest option two years ago. We screen for the one whose QA head can answer a hard question without looking at their laptop.”
How Operant Scientific approaches this
Every batch we ship is signed by a named QA reviewer on the same shift as the batch closes. Deviation investigations kick off within 24 hours; the ratio of minors to majors is a monitored quality metric. We share the last two years of inspection reports under NDA to any serious buyer, minor observations included.
If you're evaluating an Indian CDMO and want a second opinion on the questions above, the fastest way is to send us a two-line brief. We'll answer as far as we can without breaching another client's confidentiality — and tell you honestly when we can't.